Doxorubicin‐loaded poly(ε‐caprolactone)‐Pluronic micelle for targeted therapy of esophageal cancer

Abstract

There is still lack of effective treatment of esophageal cancer, and it is urgently necessary to develop a new programs to treat this disease. More and more evidence suggests that the combination of 2 or more treatment strategies can enhance the antitumor activity in cancer treatment. We have established a new therapeutic strategy that combines doxorubicin-loaded poly(ε-caprolactone) (PCL)-Pluronic micelles and miR-34a to better combat esophageal cancer. Doxorubicin was loaded into PCL-Pluronic micelle to achieve better uptake. Confocal microscopy was used to assess in vitro cellular uptake of PCL-Pluronic micelle. Finally, the in vivo effect of this new combination therapy strategy was also studied. The results showed that PCL-Plannick micelles significantly enhanced the uptake of doxorubicin in esophageal cancer cells in vitro, thereby improving the accumulation of doxorubicin in the cells. In vitro and in vivo combination of doxorubicin-loaded PCL-Pluronic micelles and miR-34a, achieving a significantly synergistic therapeutic effect over the corresponding single treatment. These results suggested that the combinational therapy based on doxorubicin-loaded PCL-Pluronic micelle and miR-34a may provide a reasonable strategy for improving the outcome of esophageal cancer treatment.

Protective Effects of Dexazoxane on Rat Ferroptosis in Doxorubicin-Induced Cardiomyopathy Through Regulating HMGB1

“…Doxorubicin (DOX) is an anticancer drug widely used in cancer treatments, including breast cancer ( 1 ), prostate cancer ( 2 ), and some other types of malignancies ( 3 , 4 ). However, the clinical use of anthracyclines is limited due to their cardiotoxic effects, including irreversible degenerative cardiomyopathy and congestive heart ( 5 ).…”

<p>A Systemic Review on the Regulatory Roles of miR-34a in Gastrointestinal Cancer</p>

“…Dai et al established a new therapeutic strategy that combines doxorubicin-loaded poly(ε-caprolactone) (PCL)-Pluronic micelles and miR-34a to combat EC. 47 In vitro and in vivo combination of doxorubicin-loaded PCLpluronic micelles and miR-34a achieved a significantly synergistic therapeutic effect over the single treatment, suggesting that miR-34a can be used to improve the anti-cancer activities of chemical drugs in the treatment of EC. However, studies on the roles of miR-34a in the treatment of EC are still needed to be further investigated.…”

Advances and challenges in the treatment of esophageal cancer

“…Dai et al. 57 reported that PCL-Plannick micelles markedly increase the absorption and accumulation of Dox in EC cells. In addition, a significant synergistic therapeutic effect was observed when combined with miR-34a .…”